8.71
+0.3(+3.57%)
Currency In USD
| Previous Close | 8.41 |
| Open | 8.53 |
| Day High | 8.71 |
| Day Low | 8.44 |
| 52-Week High | 9.03 |
| 52-Week Low | 1.87 |
| Volume | 110,711 |
| Average Volume | 1.35M |
| Market Cap | 762.22M |
| PE | -8.46 |
| EPS | -1.03 |
| Moving Average 50 Days | 7.43 |
| Moving Average 200 Days | 4.8 |
| Change | 0.3 |
If you invested $1000 in Terns Pharmaceuticals, Inc. (TERN) since IPO date, it would be worth $473.63 as of October 20, 2025 at a share price of $8.71. Whereas If you bought $1000 worth of Terns Pharmaceuticals, Inc. (TERN) shares 3 years ago, it would be worth $1,280.88 as of October 20, 2025 at a share price of $8.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
GlobeNewswire Inc.
Aug 21, 2025 8:05 PM GMT
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ETFOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
GlobeNewswire Inc.
Jun 23, 2025 8:07 PM GMT
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif.
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious d